Navigation Links
Wendy D. Lynch, Ph.D., Joins Angeion's Board of Directors

SAINT PAUL, Minn., March 5, 2012 /PRNewswire/ -- Angeion Corporation (NASDAQ: ANGN) today announced that Wendy D. Lynch, Ph.D., has been appointed to the Company's Board of Directors, effective March 1, 2012.

Dr. Lynch is currently Co-Director of the Center for Consumer Choice in Health Care at the Altarum Institute. She also currently holds a position as Adjunct Associate Professor at the School of Nursing at Indiana University/Purdue University at Indianapolis and since 2002 has served as President of Lynch Consulting, Ltd, which provides multi-disciplinary consulting focusing on Human Capital Management, Health and Productivity and Program Evaluation.

Dr. Lynch has been making the connection between employee health and business outcomes for almost 20 years. Her career includes roles as faculty at the University of Colorado Health Sciences Center, senior scientist at Health Decisions International, and principal and senior consultant at Mercer Human Resource Consulting.

"Dr. Lynch brings unique healthcare industry knowledge and experience to the Angeion Board of Directors. Her expertise across a broad spectrum of the healthcare industry, in organizational productivity, motivation, management and leadership, will be of significant strategic value to our Board.  We look forward to her insight and guidance in the direction and governance of the organization," said Mark Sheffert, Chairman of the Angeion Board of Directors.

From 2006 through 2010, Dr. Lynch also served as executive director of an education and research foundation called the Health as Human Capital Foundation, a nonprofit, non-partisan think tank providing independent information for policy makers. Dr. Lynch earned her Doctorate Degree in Research and Evaluation Methodology, her Masters Degree in Physical Education – Measurement and Exercise Physiology and her Bachelors Degree, with honors, in Physical Education, from the University of Colorado.  Her work experience includes roles as consultant, author and educator. As a consultant, Lynch has applied her skills in research design and evaluation to several pivotal studies in the fields of health management, productivity assessment and human capital management that have resulted in more than 50 published studies and articles. Most recently, she co-authored the books, "Who Survives: How Benefits Costs are Killing Your Company," and "Aligning Incentives, Information, and Choice: How to Optimize Health and Human Capital Performance."

The addition of Dr. Lynch to the board brings to seven the number of members comprising the board, five of whom are independent directors under Nasdaq Rules.

About Angeion Corporation
Founded in 1986, Angeion Corporation acquired Medical Graphics Corporation in December 1999. Medical Graphics develops, manufactures and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics ( and New Leaf ( brand names. These cardiorespiratory product lines provide solutions for disease detection, integrated care, and wellness across the entire spectrum of health – whether managing chronic illness, promoting fitness, or training for the Olympics. The Company's products are sold internationally through distributors and in the United States through a direct sales force that targets heart and lung specialists located in hospitals, university-based medical centers, medical clinics and physicians' offices, pharmaceutical companies, medical device manufacturers, clinical research organizations, health and fitness clubs, personal training studios, and other exercise facilities. For more information about Angeion, visit

Forward Looking Statements
Press releases and other statements by Angeion may contain forward-looking statements about Angeion's future financial results and business prospects that by their nature involve substantial risks and uncertainties.  You can identify these statements by the use of words such as "anticipate," "believe," "estimate," "expect," "project," "intend," "plan," "will," "target," and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or business plans or prospects.  Our actual results may differ materially depending on a variety of factors including: (1) national and worldwide economic and capital market conditions; (2) continuing cost-containment efforts in our hospital, clinic, and office markets; (3) remaining as a qualified provider for large group purchasing organizations, thereby ensuring continued access to our market and efficiently increasing our sales potential to expanded numbers of companies using these buying groups; (4) any changes in the patterns of medical reimbursement that may result from national healthcare reform; (5) our ability to successfully operate our business, including successfully converting our increasing research and development expenditures into new and improved cardiorespiratory diagnostic products and services and selling these products and services under the MedGraphics and New Leaf brand names into existing and new markets; (6) our ability to complete our software development initiatives and migrate our MedGraphics and New Leaf platforms to a next generation technology; (7) our ability to maintain our cost structure at a level that is appropriate to our near to mid-term revenue expectations and that will enable us to increase revenues and profitability as opportunities develop; (8) our ability to achieve constant margins for our products and consistent and predictable operating expenses in light of variable revenues from our clinical research customers; (9) our ability to expand our international revenue through our distribution partners and our Milan, Italy representative branch office; (10) our ability to successfully defend ourselves from product liability claims related to our cardiorespiratory diagnostic products and claims associated with our prior cardiac stimulation products; (11) our ability to defend our existing intellectual property and obtain protection for intellectual property we develop in the future; (12) our ability to develop and maintain an effective system of internal controls and procedures and disclosure controls and procedures; (13) our dependence on third-party vendors; and (14) the ability of new members of our senior management to make a successful transition into their new roles and for all members of senior management to ultimately develop and implement a strategic plan.  These and other risk factors that are described from time to time in the Company's Securities and Exchange Commission reports, including the Annual Report on Form 10-K for the year ended October 31, 2011.Contact:

Gregg O. Lehman, Ph.D.

Joe Dorame, Robert Blum, Joe Diaz 

Angeion Corporation

Lytham Partners, LLC 

Chief Executive Officer and President

(602) 889-9700 

(651) 484-4874

SOURCE Angeion Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen(R) Therapeutics Appoints Wendy Dixon, Ph.D. to Board of Directors
2. Essentialis Appoints Mahendra G. Shah, Ph.D., to Board of Directors
3. Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice President of Research & Development
4. Thomas Dietz, Ph.D., Elected Chairman of Galleon Pharmaceuticals
5. White Smile Global Inc. (WSML) Names Dr. Martin S. Giniger, D.M.D., Ph.D., MsD, FICD New Scientific Director Bringing Decades of Proven Scientific Advancements to Create the All New White Smile™ Organic Product Line
6. Anaphore Appoints Michael F. Haller, Ph.D., Senior Vice President of Strategic Partnerships and H Casey Logan Senior Vice President of Business Development
7. Inhibikase Therapeutics Elects Steven C. Gilman, Ph.D., to Board of Directors
8. Mercator MedSystems Appoints Neil Desai, Ph.D., to Board of Directors
9. Pharmaceutical Institute Hires Nathan Pienkowski, Ph.D., to Head Instructional Design
10. Otonomy Appoints David A. Weber, Ph.D., Chief Executive Officer
11. Sutro Biopharma Appoints Trevor Hallam, Ph.D., as Chief Scientific Officer
Post Your Comments:
(Date:10/13/2015)... , Oct. 13, 2015  EndoChoice Holdings, Inc. ... third quarter 2015 financial results on Thursday, November 5, ... . --> . ... Thursday, November 5, 2015 at 9:00 a.m. ET to ... for domestic callers and (412) 317-5469 for international callers. ...
(Date:10/13/2015)... , Oct. 13, 2015   Rosa & ... firm in Quantitative Systems Pharmacology (QSP)/ PhysioPD™ , today ... will lead a workshop at the QSP Congress ... Boston, MA.  The conference focuses ... drug development.  Dr. Friedrich,s workshop is entitled "Using Mechanistic ...
(Date:10/13/2015)... 13, 2015  Yesterday Congresswoman Renee Ellmers ... manufacturing site located in Holly Springs, NC ... produced Flucelvax ® (Influenza Vaccine) using cell-culture technology, a ... start-up and is not reliant on chicken eggs. 1,2 ... influenza vaccines business of Novartis AG in the US, ...
Breaking Medicine Technology:
(Date:10/13/2015)... , ... October 13, 2015 , ... ... review of Anik Singal's newly launched "Publish Academy" training course . Singal's ... business opened for enrollment today, and marketers around the Internet are weighing in ...
(Date:10/13/2015)... ... October 13, 2015 , ... T-System and Centegra ... than 59,000 emergency department visits per year, today announced the successful and rapid ... improve clinical, operational and financial outcomes. , In less than four ...
(Date:10/13/2015)... ... , ... Local Gold’s Gym franchise owner, Bryce Berry, received the Visionary of ... owns and operates Gold's Gym Cheyenne in Cheyenne, Wyoming, received the award ... States. A brand leader in global fitness, Gold’s Gyms are located worldwide. Every fitness ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... Affinity have developed valuable new strategies for enrolling and serving insurance consumers who ... to obtain health insurance and pay monthly premiums. In “Health Plan Engagement Strategies: ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... team: Debbie Vereb has been named the organization’s Executive Vice President of ... have been hired to key leadership roles in the company. , Debbie Vereb’s ...
Breaking Medicine News(10 mins):